Perceptic, a startup founded by former Palantir executives, has emerged from stealth mode with a $12 million seed funding round aimed at revolutionizing drug discovery through an end-to-end AI platform. The company, which has already garnered interest from major pharmaceutical firms, is designed to streamline the drug development process from discovery to clinical trial design.
The funding round was led by Accel, with participation from Air Street Capital and Elder Gull. Although the company has not disclosed its valuation, it has begun to attract attention for its innovative approach. Perceptic’s platform aims to act as a cohesive layer that integrates various AI tools and data sources, addressing a significant gap in the current drug development landscape.
Perceptic's co-founder and CEO, Tilman Flock, emphasizes that existing AI solutions often focus on isolated aspects of drug development, leading to inefficiencies. In contrast, Perceptic seeks to unify these efforts, enabling pharmaceutical companies to make informed decisions more quickly. The platform is designed to help with three key areas: assessing external biotech assets, selecting clinical trial indications, and building a robust data foundation for trial design.
With a growing team and plans for expansion, Perceptic aims to reshape the pharmaceutical R&D landscape. The startup's ability to harmonize various data types while maintaining traceability is particularly appealing to pharmaceutical companies, which require reliable data provenance. This innovative approach could signify a shift in enterprise AI, moving towards integrated systems that unify workflows across departments, potentially transforming how pharmaceutical companies operate.